Are two newly identified SNPs in the APO AI-CIII intergenic region strongly associated with familial combined hyperlipidaemia?
These newly identified additional intergenic SNPs therefore provide an alternative explanation for the observed association of the SstI and MspI polymorphisms to the increased susceptibility for FCHL.
The degree of endoscopic inflammation correlates to response to natalizumab and maintenance of remission. These findings provide prognostic information for patient management decisions.